Summary
• HeartBeam, Inc. (BEAT) shares rise 1.7% to $3.50 following FDA clearance of a cable-free ECG for at-home arrhythmia monitoring.
• Analyst ratings upgraded to “Buy,” with Benchmark raising its rating and HC Wainwright significantly increasing its price target from $2.50 to $5.50.
• Strong trading activity with 10-day average volume over 80 million, indicating heightened investor interest and bullish momentum.
HeartBeam, Inc. (BEAT) is seeing a price increase of 1.7% in intraday trading, currently priced at $3.50. This move comes as the company continues to attract attention following its recent FDA clearance announcement.
FDA Clearance Sparks Investor Interest
On December 10, 2025, HeartBeam received FDA clearance for its innovative cable-free synthesized 12-lead ECG, which is designed for at-home arrhythmia assessment. This significant regulatory milestone positions the company to offer an advanced solution in remote heart monitoring, enhancing its growth potential within the medical technology sector. The excitement around this approval has contributed to increased investor engagement with BEAT stock.
Analyst sentiment reflects optimism as well, with the stock rated as a “Buy” by several analysts. Benchmark upgraded its rating from “Speculative Buy” to “Buy” on December 11, 2025, reinforcing confidence in the company following the FDA announcement.
Market and Technical Picture
HeartBeam’s performance metrics reveal a strong upward trajectory, with quarterly performance at 144% and yearly performance at 14%. Additionally, the stock has shown impressive volatility, with an ATR of 0.43 and a 14-day RSI of 84.23, suggesting that the stock is currently overbought.
The average volume for the past 10 days stands at over 80 million, significantly higher than the 3-month average of approximately 10.8 million, indicating heightened trading activity. The stock is trading well above its 20-day and 50-day moving averages, at 168% and 127% respectively, reflecting sustained bullish momentum.
Analyst Ratings Overview
The recent analyst ratings indicate a positive outlook on BEAT. Alongside the recent upgrade from Benchmark, HC Wainwright & Co. maintained its “Buy” rating while adjusting the price target significantly upward from $2.50 to $5.50, illustrating strong belief in the company’s future performance. This combination of upgrade activity is likely influencing investor sentiment positively.
Outlook
With investors responding favorably to the FDA’s clearance and an optimistic analyst outlook, HeartBeam appears to be on an upward trend. As the company leverages its innovative technology in the healthcare space, it remains well-positioned for continued growth.